Bioceltix S.A. (BCX.WA)
PLN 79.8
(4.04%)
PLN 79.8
(4.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 175.05 Thousand PLN | -40.45% |
| 2022 | 293.94 Thousand PLN | -44.63% |
| 2021 | 530.83 Thousand PLN | 409.6% |
| 2020 | 104.16 Thousand PLN | -36.87% |
| 2019 | 165 Thousand PLN | 0.0% |
| 2018 | - PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 270.57 Thousand PLN | 54.56% |
| 2024 Q2 | 210.02 Thousand PLN | -22.38% |
| 2023 FY | 175.05 Thousand PLN | -40.45% |
| 2023 Q1 | 258.72 Thousand PLN | -11.98% |
| 2023 Q4 | 175.05 Thousand PLN | -14.38% |
| 2023 Q3 | 204.44 Thousand PLN | -11.56% |
| 2023 Q2 | 231.17 Thousand PLN | -10.65% |
| 2022 Q4 | 293.94 Thousand PLN | -21.71% |
| 2022 Q2 | 120.27 Thousand PLN | 0.0% |
| 2022 Q1 | - PLN | 0.0% |
| 2022 Q3 | 375.47 Thousand PLN | 212.19% |
| 2021 Q3 | - PLN | 0.0% |
| 2021 Q4 | - PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BIOTON S.A. | 68.69 Million PLN | 99.745% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | 95.366% |
| Mabion S.A. | 35.82 Million PLN | 99.511% |
| Molecure S.A. | 7.13 Million PLN | 97.548% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | 3.283% |
| Poltreg S.A. | 8.19 Million PLN | 97.864% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | 98.647% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | 80.678% |
| Synthaverse S.A. | 70.04 Million PLN | 99.75% |
| Urteste S.A. | 627 Thousand PLN | 72.08% |